This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology
npj Precision Oncology Open Access 30 January 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
US Food and Drug Administration. https://go.nature.com/41xD0em (2022).
US Food and Drug Administration. https://go.nature.com/3zefINL (2019).
Bitterman, D. S. et al. Lancet Digit. Health 2, e447–e449 (2020).
He, J. et al. Nat. Med. 25, 30–36 (2019).
Reyes, M. et al. Radiol. Artif. Intell. 2, e190043 (2020).
Kaushal, A. et al. JAMA 324, 1212–1213 (2020).
Panch, T. et al. J. Glob. Health 9, 010318 (2019).
Finlayson, S. G. et al. N. Engl. J. Med. 385, 283–286 (2021).
US Department of Health and Human Services. 45 CFR 46 https://go.nature.com/3yl1Rq4 (2018).
The Pew Charitable Trusts. https://go.nature.com/3I4ZuwJ (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.S.B. is an associate editor of Radiation Oncology, HemOnc.org, unrelated to this work, for which she receives no financial compensation; and funding from American Association for Cancer Research, unrelated to this work.
Rights and permissions
About this article
Cite this article
Perni, S., Lehmann, L.S. & Bitterman, D.S. Patients should be informed when AI systems are used in clinical trials. Nat Med 29, 1890–1891 (2023). https://doi.org/10.1038/s41591-023-02367-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02367-8
This article is cited by
-
New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology
npj Precision Oncology (2024)